DigestRedComo funciona
Red
/
Empresas
Bi
No verificado

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

16 Comunicados de prensa

Ver todos los comunicados de prensa
05/12/2025
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
05/12/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Mercado laboral
Industria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
16/09/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
16/09/2025
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
04/09/2025
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
04/09/2025
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
10/07/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Mercado laboral
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
10/07/2025
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
05/06/2025
Industria
Ciencia
Material médico sanitario
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Salud
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0
04/06/2025
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Óptica
Biotecnología
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Fuente
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0